OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Wang on Research With Menin Inhibitors in AML/ALL

August 2nd 2024

Eunice Wang, MD, discusses ongoing research with menin inhibitors in patients with acute leukemias, as presented at the 2024 EHA Congress.

Dr Rotow on Challenges With Targeting CNS Metastases in Lung Cancer

August 1st 2024

Julia Rotow, MD, discusses existing unmet needs for patients with lung cancer and CNS metastases.

Dr Rijneveld on the Addition of Blinatumomab to Prephase and Consolidation Therapy in B-ALL

August 1st 2024

Anita Rijneveld, MD, discusses outcomes with the addition of blinatumomab to prephase and consolidation therapy for patients with adult B-cell acute lymphoblastic leukemia.

Dr Backhus on Defining Borderline-Resectable Lung Cancer

August 1st 2024

Leah Backhus, MD, MPH, FACS, discusses the evolving definition of borderline resectable lung cancer.

Dr Jimenez Jimenez on the Clinical Implications of the ACCESS Trial in Hematological Malignancies

August 1st 2024

Antonio Martin Jimenez Jimenez, MD, discusses the clinical implications of PBSC from HLA-MMUD and PTCy for GVHD prophylaxis in hematological malignancies.

Dr Platzbecker on First-Line ATRA/ATO in High-Risk Acute Promyelocytic Leukemia

July 31st 2024

Uwe Platzbecker, MD, discusses efficacy data with the combination of all-trans retinoic acid and arsenic trioxide in high-risk acute promyelocytic leukemia.

Dr Opat on the Accessibility of Sonrotoclax Plus Zanubrutinib in R/R CLL/SLL

July 31st 2024

Stephen Opat, MBBS, discusses the accessibility of sonrotoclax plus zanubrutinib in relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

Dr Uzzo on a Biomarker Analysis of the IMmotion010 Trial in RCC

July 31st 2024

Robert Uzzo, MD, MBA, FACS, discusses a biomarker analysis of the IMmotion010 trial in patients with renal cell carcinoma.

Dr Choudhury on Survival Advantages With AR Pathway Inhibitors in mHSPC

July 31st 2024

Atish D. Choudhury, MD, PhD, discusses the background of the A-DREAM trial in patients with metastatic hormone-sensitive prostate cancer.

Dr Bekaii-Saab on the Future of Treatment For Patients With GI Cancer

July 31st 2024

Tanios Bekaii-Saab, MD, FACP, discusses the future of treatment within the gastrointestinal cancers armamentarium.

Dr Msaouel on Ongoing Research With Bispecific Antibodies in RMC and Epithelioid Sarcoma

July 31st 2024

Dr Dreicer on Managing Biochemical Failure Post-Radical Prostatectomy in Prostate Cancer

July 31st 2024

Robert Dreicer, MD, discusses complexities surrounding biochemical failure post radical prostatectomy in patients with prostate cancer.

Dr Wong on Challenges Incorporating Checkpoint Inhibitors into Curative-Intent Regimens in HNSCC

July 31st 2024

Deborah J. Wong, MD, PhD, discusses challenges incorporating checkpoint inhibitors into curative-intent approaches for patients with head and neck squamous cell carcinoma.

Dr Lynce on the Prognosis of Patients With Inflammatory Breast Cancer

July 30th 2024

Filipa Lynce, MD, discusses the current prognosis of patients diagnosed with inflammatory breast cancer subtypes.

Dr Shields on Incorporating Tarlatamab into Clinical Practice for ES-SCLC

July 30th 2024

Misty D. Shields, MD, PhD, discusses the FDA approval of tarlatamab for patients with extensive-stage small cell lung cancer.

Dr Riess on Advancements in Thymic Epithelial Malignancy Management

July 30th 2024

Jonathan W. Riess, MD, MS, discusses advancements, as well as unmet needs in the management of thymic malignancies.

Dr Nawfal on Radiological Tumor Burden as an Independent Prognostic Factor of Survival in mccRCC

July 30th 2024

Rashad Nawfal, MD, discusses radiological tumor burden as an independent prognostic factor for survival in metastatic clear cell renal cell carcinoma.

Dr Pollyea on the Mechanism of Revumenib in KMT2A-Rearranged R/R AML

July 30th 2024

Dan Pollyea, MD, MS, discusses the mechanism of action for the menin inhibitor revumenib in KMT2A-rearranged relapsed/refractory acute myeloid leukemia.

Dr Patel on Areas of Advancement in the NSCLC Treatment Landscape

July 30th 2024

Sandip P. Patel, MD, discusses significant areas of advancements in the treatment paradigm for non–small cell lung cancer.

Dr Desai on Unmet Needs With Chemoimmunotherapy in NSCLC

July 30th 2024

akash Desai, MBBS, MPH, discusses unmet needs with the use of chemoimmunotherapy in patients with non–small cell lung cancer.